On November 20, 2020 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported that it will host a virtual Investor Day today, which will feature the Company’s Senior Leadership team and Dr Dejka Araujo of the MD Anderson Cancer Cente (Press release, Adaptimmune, NOV 20, 2020, View Source [SID1234571478])r. The link to register is HERE and further background information on Adaptimmune and the event can be found HERE. After the event, a copy of the presentation materials and webcast links will be posted on the Events and Presentations page under the Investors section of the Adaptimmune website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will lay out the strategy confirming our leadership position as a company designing and delivering cell therapies for people with cancer," said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. "Over the next five years, we plan to deliver two marketed products, one in sarcoma and one in gastroesophageal cancers, and two additional BLAs in other solid tumor indications. We also plan to develop a robust autologous and allogeneic clinical pipeline that takes us towards the ultimate goal of curative and mainstream cell therapies for people with cancer."

Adaptimmune’s Virtual Investor Day will cover the following topics:

Opening Remarks by Adrian Rawcliffe, CEO

Strategic vision for Adaptimmune and core value drivers for the next five years
Delivering TCR T-cell therapies and building the cell therapy company of the future ​
MAGE-A4 is a target with large market potential across a broad range of solid tumor indications including synovial sarcoma, lung, head and neck, bladder, and gastroesophageal cancers
Synovial sarcoma care: the need for cell therapy

Dejka Araujo, M.D. (Professor in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center) will discuss the current treatment landscape and unmet medical need for people with synovial sarcoma
Driving towards delivery of two marketed products and two further BLAs by 2025

An overview of plans to launch the first TCR T-cell therapy (ADP-A2M4) in synovial sarcoma as enrollment in the SPEARHEAD-1 trial is on track
Plan to file a BLA with ADP-A2M4D8 in gastroesophageal cancers in 2024
Potential addressable population across all tumor types with significant MAGE-A4 expression of ~39,000 patients per year in the US and EU factored for HLA-A21; additional BLA(s) projected with ADP-A2M4CD8 in tumor types beyond gastroesophageal cancers
Additional BLA projected for ADP-A2AFP (first or next-generation CD8α) with a potential market opportunity of ~16,000 patients per year based on serum AFP expression1 and factoring for HLA-A2
Plan to incorporate next-generation CD8α enhancement into SPEAR T-cells targeting AFP in a clinical trial next year
The importance of building an integrated cell therapy company for rapid execution and success

An overview of the Company’s integrated structure with its leading capabilities for designing and delivering cell therapies
Case studies demonstrating the value that this integrated approach has delivered: rapid execution of clinical programs, security of vector supply, reduction of costs, and learnings applied to the allogeneic platform
A rich cell therapy pipeline for the future over the next 5 years

Focusing on curative intent: leveraging translational insights for best next-generation products:
Positioning multiple enhancements for next-generation SPEAR T-cells including:
ADP-A2M4 SPEAR T-cells co-expressing IL-7, IL-15, dnTGFβ, and/ or PDE7
Enhancing SPEAR T-cells with IL-7 for proliferation and survival and CCL19 for migration into tumor in collaboration with Noile-Immune
Enhancing SPEAR T-cells using transmembrane and surface immunoregulatory mechanisms with Alpine Immune Sciences
Focusing on enabling mainstream access – broadening patient coverage and patient access:
Plans to expand into HLAs beyond A2 to increase the addressable patient population
Bringing forward HiT candidates for multiple targets including GPC3
Announcing collaboration with leading TIL therapy center (CCIT, Denmark) for nextgeneration TILs co-expressing IL-7
Bringing two allogeneic targets into the clinic:
In-house MAGE A4 targeted iPSC T-cell products
Mesothelin, a target expressed in multiple solid tumors, named as first HiT target in partnership with Astellas
An update on the Company’s financial position

Total liquidity position of $400 million as of September 30, 2020
Current cash runway into early 2023
The Virtual Investor Day will also include two Q&A sessions.